Using 18F-FAPI PET scans for unknown primary cancers
Part of Cancer clinical trials.
This trial tests a special scan (18F-FAPI PET) to help find where a cancer started when the origin is unknown. The goal is to better locate the hidden tumor and guide treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a cancer that started in an unknown part of the body (called cancer of unknown primary).
- You are scheduled or willing to have a special scan called an 18F-FAPI PET scan.
- You have not had any other cancer in the past 5 years.
- You do not have any other serious or life-threatening illness that is not under control.
- You are able to understand the study and give your permission (informed consent).
- If you are pregnant or breastfeeding, you cannot join this trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new type of PET scan that may help doctors see lung cancer more clearly. You may be able to join if you have lung cancer and are able to get this scan.
This trial tests a new imaging agent (18F-FAPI) to see if it can help find tumors early in people with lung, thyroid, pancreatic, melanoma, or neuroendocrine cancers.
This study uses a special PET scan called FAPI to help find or monitor solid tumors. It may help doctors see tumors more clearly and guide treatment decisions.
This study tests a new type of PET-CT scan using a tracer called FAPI to find the original source of cancer when standard tests have not been able to. It may help identify the primary tumor in people with cancer that has spread from an unknown location.
This study tests a new type of PET scan that uses a special tracer called FAPI to find where cancer has spread in your body. It may help doctors see hidden tumors more clearly without needing extra treatments first.
This trial tests a PET scan (a type of imaging) that targets cells in the body that help support cancers. It may help doctors better see where cancer-associated cells are located, which could guide future cancer care.
Hear when a new Cancer of Unknown Primary Site trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.